Christopher Mutz - 15 Feb 2022 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Reporting relationship: HEAD OF RARE DISEASE
Issuer ticker: ANIP
Reported as of: 15 Feb 2022
Net transaction value: -$47,656
SEC form: 4
Accepted by SEC: 17 Feb 2022, 18:24:41 UTC
Next SEC filing: 28 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Christopher Mutz

Key filing fact

Christopher Mutz filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 17 Feb 2022.

Key facts

This page summarizes Christopher Mutz's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Feb 2022, 18:24.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$47,656.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANIP transaction

Common Stock

Tax liability

Transaction value: $47,656
Shares: -1,184
Change %: -7.3%
Price: $40.25
Shares after: 14,950
Date: 15 Feb 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,033 shares of restricted stock, the grant of which was previously reported.